ArticleCell death & disease2026
Adipogenic transdifferentiation reprograms EMT-high PDAC cells into a post-mitotic adipocyte-like state and limits metastasis.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a notoriously lethal malignancy with high epithelial-mesenchymal transition (EMT) baseline. EMT is associated with enhanced cell plasticity and contributes to tumor adaption and evolution. EMT programs fuel PDAC invasion, metastasis, and treatment resistance, but directly targeting EMT has yielded limited clinical benefits. Transdifferentiation therapy that exploits cell plasticity and redirects malignant cell fate offers an orthogonal approach beyond pathway inhibition. To validate the feasibility of transdifferentiation in epithelial malignancies such as PDAC, we applied an adipogenesis protocol in seven human PDAC cell lines and distinguished AsPC-1 with intensified adipocyte features (intracellular lipid droplets accumulation, elevated adiponectin, CEBPA, PPARG, FABP4 expression). AsPC-1 was converted into adipocyte-like, post-mitotic cells with lipometabolic (enhanced adiponectin secretion and lipolysis) and phenotypic reprogramming (proliferation inhibition, G1 cell cycle arrest, and EMT key transcription factors downregulation). Multi-omics showed global chromatin compaction and transcriptome-wide repression of EMT and metastatic programs in induced AsPC-1 cells, with suppressed MMPs and TGF-β, indicating diminished metastatic potential. Therefore, we further evaluated the possibility of clinical translation by murine orthotopic and hepatic metastasis models, finding adipogenesis induction reduced primary tumor burden and slowed metastatic progression. The adipocyte-like phenotype in vivo was sustained through one-month observation period following induction drug withdrawal. This study establishes a plasticity-oriented "convert-instead-of-kill" strategy for EMT-high PDAC, suggesting a potential for future studies to investigate rational combinations (e.g., transdifferentiation therapy combined with targeted or immunotherapy) to exploit lineage conversion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.